510 related articles for article (PubMed ID: 26517810)
1. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
2. Integrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatment.
Hu G; Zhang H; Zhang L; Ruan S; He Q; Gao H
Int J Pharm; 2015 Dec; 496(2):1057-68. PubMed ID: 26598487
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe
Shen JM; Li XX; Fan LL; Zhou X; Han JM; Jia MK; Wu LF; Zhang XX; Chen J
Int J Nanomedicine; 2017; 12():1183-1200. PubMed ID: 28243083
[TBL] [Abstract][Full Text] [Related]
4. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
5. A size switchable nanoplatform for targeting the tumor microenvironment and deep tumor penetration.
Cun X; Li M; Wang S; Wang Y; Wang J; Lu Z; Yang R; Tang X; Zhang Z; He Q
Nanoscale; 2018 May; 10(21):9935-9948. PubMed ID: 29770822
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release.
Ruan S; Cao X; Cun X; Hu G; Zhou Y; Zhang Y; Lu L; He Q; Gao H
Biomaterials; 2015 Aug; 60():100-10. PubMed ID: 25988725
[TBL] [Abstract][Full Text] [Related]
7. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
8. Size-shrinkable and protein kinase Cα-recognizable nanoparticles for deep tumor penetration and cellular internalization.
Ma JB; Shen JM; Yue T; Wu ZY; Zhang XL
Eur J Pharm Sci; 2021 Apr; 159():105693. PubMed ID: 33383133
[TBL] [Abstract][Full Text] [Related]
9. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
10. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
11. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma.
Ruan S; He Q; Gao H
Nanoscale; 2015 Jun; 7(21):9487-96. PubMed ID: 25909483
[TBL] [Abstract][Full Text] [Related]
13. Na
Araste F; Abnous K; Hashemi M; Dehshahri A; Detampel P; Alibolandi M; Ramezani M
Eur J Pharm Sci; 2020 Feb; 143():105207. PubMed ID: 31870814
[TBL] [Abstract][Full Text] [Related]
14. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
16. [Construction and Anti-tumor Effect Evaluation of a Dual-Responsive Hyaluronic Acid Carbon Quantum Dot-Gelatin Nano-Drug Delivery System].
Li M; Li JP; Wang YS; He Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):577-584. PubMed ID: 34323034
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
[TBL] [Abstract][Full Text] [Related]
18. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
